Eris Lifesciences reported FY26 consolidated revenue growth of 8.1% to Rs. 3,129 crore and EBITDA growth of 10.1% to Rs. 1,120 crore.
The Domestic Branded Formulations (DBF) segment grew 11% with a 37% EBITDA margin, driven by strong Insulin and Derma performance.
The company launched its Gx Semaglutide brand 'Sundae', achieving a #1 rank by sale volume and #2 by sale value in its first month.
The International Business missed its FY26 target, reporting Rs. 348 crore revenue due to supply chain disruptions and EU-GMP audit observations.